News

Opthea Set to Engage Investors at a Major Healthcare Conference

Opthea Set to Engage Investors at a Major Healthcare Conference

Opthea to Attend the Citi 2024 Global Healthcare Conference

Opthea Limited (NASDAQ: OPT), a pioneering biopharmaceutical company focused on developing innovative treatments for serious retinal diseases, is making headlines as it gears up to participate in the prominent Citi 2024 Global Healthcare Conference. The event provides an exceptional platform for Opthea to share its insights and updates with investors.

Key Conference Participation Details

Fred Guerard, PharmD, who serves as the Chief Executive Officer of Opthea, will lead the charge in engaging with investors. He will facilitate one-on-one meetings, offering personalized insights into the company’s trajectory. Additionally, Guerard will take part in a panel discussion aimed at addressing critical issues in ophthalmology, titled "Eyes Wide Open on Ophthalmology." This session is an exciting opportunity to highlight advancements in managing retinal diseases, particularly wet age-related macular degeneration (wet AMD).

Panel and Presentation Information

The conference is scheduled for December 5, 2024, making it a key date for stakeholders interested in the latest developments in the biopharmaceutical sector. Guerard’s presentation is set for 1:45 PM ET, during which he will discuss the company's innovative approaches and future plans.

Innovative Therapies from Opthea

At the heart of Opthea's mission is its lead candidate, sozinibercept. This groundbreaking therapy is designed to meet the crucial needs in treating retinal diseases that are significantly affecting patients' lives. Currently, sozinibercept is undergoing rigorous testing in two pivotal Phase 3 clinical trials known as COAST and ShORe. These trials are essential for determining the therapy's efficacy when used alongside existing anti-VEGF-A treatments, aiming to enhance patient outcomes substantially.

Continuous Progress in Clinical Trials

The ongoing trials have shown promise, indicating that sozinibercept may deliver superior vision improvements compared to current standard treatments for wet AMD and diabetic macular edema (DME). This progress is crucial as it reflects Opthea's commitment to addressing the unmet medical needs of patients facing these debilitating conditions.

Engagement with the Community

Opthea invites everyone interested in their innovative projects to visit their website, where they will provide real-time updates during the conference. Stakeholders can gain insights into the company’s clinical trials, product developments, and their overarching vision for the future of retinal disease treatment.

Investor and Media Inquiries

For those keen to learn more or engage with the company further, Opthea encourages inquiries through their investor relations and media contacts. PJ Kelleher of LifeSci Advisors, LLC, is available for investor-related questions, while Silvana Guerci-Lena from NorthStream Global Partners handles media inquiries. Their dedication to clear communication showcases Opthea's readiness to foster relationships with investors and the public alike.

Frequently Asked Questions

What is Opthea's primary focus?

Opthea primarily focuses on developing innovative therapies for retinal diseases, especially wet age-related macular degeneration and diabetic macular edema.

Who will be presenting at the Citi conference?

Fred Guerard, the CEO of Opthea, will be presenting at the conference and leading discussions with investors.

When is the Citi 2024 Global Healthcare Conference?

The conference is scheduled for December 5, 2024, where Opthea's participation includes investor meetings and a panel discussion.

What is sozinibercept?

Sozinibercept is Opthea's lead product candidate aimed at improving treatment outcomes for retinal diseases through enhanced efficacy when combined with existing therapies.

How can I learn more about Opthea's developments?

Interested individuals can visit Opthea's website and follow its updates on social media platforms for the latest news and developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 94

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading

Top 5 Most Recently Viewed Articles

APh ePower's 2025 R&D Achievement: Transforming Elevator Energy

Updated Category News Views 178

APh ePower's Remarkable Innovation Award The leader in aluminum battery technology is not only setting standards for efficiency but is also making strides in sustainability. Recently, APh ePower was honored with the prestigious 2025 R&D 100 Award for its groundbreaking Elevator Regenerative Power System (ERPS). This award highlights the company's efforts in redefining...

Continue Reading
Butterfly Completes $300 Million Loan for Milk Specialties Growth

Updated Category News Views 349

Butterfly Completes Major Dividend Recapitalization Butterfly, a well-known private equity firm based in Los Angeles, has made a significant move in the food industry by securing a substantial $300 million second lien term loan facility. This funding is intended to support Milk Specialties Global, an important portfolio company recognized for its innovative methods in...

Continue Reading
Rezolve Ai Enhances BRAiN Assistant for Optimal User Engagement

Updated Category News Views 73

Rezolve Ai Introduces Key Updates to BRAiN Assistant Rezolve Ai (Nasdaq: RZLV) has made a bold move in the realm of AI technology with a substantial update to its BRAiN Assistant. This upgraded platform is designed to significantly enhance user experience and response accuracy, reinforcing the company's dedication to harnessing innovative technology for superior AI-driven...

Continue Reading
Minesto Teams Up to Unlock Tidal Power in Maldives

Updated Category News Views 270

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

Continue Reading
Promising New Insights on Dual Masked T-Cell Engagers from Vir

Updated Category News Views 216

Encouraging Developments in Cancer Treatment by Vir Biotechnology Vir Biotechnology, Inc. (NASDAQ: VIR) has recently shared commendable initial Phase 1 data regarding their innovative dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500. These breakthroughs target challenging forms of cancer, notably HER2-expressing solid tumors and metastatic castration-resistant...

Continue Reading